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Abstract 
In this paper we report the synthesis, in vitro anticancer activity, and the 
experimental/computational characterization of mechanism of action of a new series of E isomers of 
triazolo[4,5-b/c]pyridin-acrylonitrile derivatives (6c-g, 7d-e, 8d-e, 9c-f, 10d-e, 11d-e). All new 
compounds are endowed with moderate to interesting antiproliferative activity against 9 different 
cancer cell lines derived from solid and hematological human tumors. Fluorescence-based assays 
prove that these molecules interfere with tubulin polymerization. Furthermore, isothermal titration 
calorimetry (ITC) provides full tubulin/compound binding thermodynamics, thereby ultimately 
qualifying and quantifying the interactions of these molecular series with the target protein. Lastly, 
the analysis based on the tight coupling of in vitro and in silico modelling of the interactions 
between tubulin and the title compounds allows to propose a molecular rationale for their biological 
activity.  
 
Keywords: Triazolo[4,5-b/c]pyridin-acrylonitriles, Antiproliferative activity, Tubulin 
polymerization, Molecular modeling, Isothermal titration calorimetry, Fluorescence-based assays 
 
1. Introduction 
Incontrollable cell proliferation constitute the basis for malignant tumor emergence. Various 
chemotherapeutic agents can reach different molecular targets affecting the proliferation process. 
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Among these, structurally complex natural products such as paclitaxel, vinblastine, and vincristine 
are potent microtubules-targeting drugs [1] widely used in the treatment of cancer. Microtubules are 
cytoskeletal polymers that play a key role in the regulation of processes such as segregation of 
chromosomes during mitosis, intracellular transport and cellular shape. Their basic structural unit is 
constituted by assembled/disassembled α,β-tubulin heterodimers in a dynamic system. Specific 
binding sites for inhibitors can be identified on the heterodimers [2]. Consequent to this interaction, 
inhibitors suppress tubulin dynamic instability and interfere with microtubule functions, including 
mitotic spindle formation. This event blocks mitosis and arrests the cell cycle in the G2/M phase, 
ultimately leading to apoptosis [3].  
Microtubule-targeting agents are classified into two categories: 1) molecules binding to the 
vinblastine and colchicine binding site and inhibiting tubulin assembly are defined as microtubule 
destabilizing agents; 2) molecules binding to the tubulin paclitaxel-binding site are defined as 
microtubule-stabilizing agents [4]. Actually, colchicine and its structurally analogues are not used in 
clinical settings as they are too toxic at therapeutic doses. However, synthetic compounds able to 
bind to the colchicine-binding site are currently undergoing clinical development and evaluation in 
patients with a wide array of cancers [5]. 
Recently we reported the synthesis and evaluation as antiproliferative agents of some benzotriazol-
(1)-yl-3-phenylacrylonitrile derivatives [6, 7], and demonstrated that this series of compounds act 
on the G2/M phase of the cell cycle. This behavior was consistent with a possible tubulin binding 
activity; accordingly, we confirmed this hypothesis using competition experiments in which the 
reference compound (E-2-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(benzo[d][1,3]dioxol-5-
yl)acrylonitrile strongly displaced radio labeled colchicine from its tubulin binding site, with an IC50 
value lower than colchicine itself (0.85 µM and 1.02 µM, respectively) [8]. 
Molecular modeling studies of the putative binding mode of this series of compounds on tubulin 
further supported this finding [8]. As previously observed, substitutions with electron donor (i.e 
methyl group) and electro withdrawing (i.e. chlorine) groups on the phenyl moiety of benzotriazole 
did not lead to enhanced activity, unsubstituted benzotriazole remaining the most promising 
scaffold. Actually, with the twofold goal of improving the antiproliferative potency and the 
physicochemical properties of these derivatives, we modified the main scaffold and substituted the 
benzotriazole group with a 3H-[1,2,3]triazolo[4,5-b]pyridine or a 3H-[1,2,3]triazolo[4,5-c]pyridine 
moiety.  
Indeed, we speculated that the steric hindrance exerted by the presence of a bulky group (e.g., 
methyl or chlorine) on the benzotriazole moiety could be more deleterious to the biological activity 
of the resulting compounds than their electronic contribution. So we decided to preserve an 
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electron-withdrawing group on this moiety, maintaining at the same time the steric hindrance only 
on the other phenyl, to speed up the Knoevenagel condensation and to obtain E-stereoselective 
synthesis, as previously observed [6-9]. For these reasons, we chose to introduce a nitrogen on the 
phenyl side of benzotriazole moiety, simultaneously evaluating the relevance of its relative position. 
The electron-withdrawing nitrogen in pyridine makes the deprotonated intermediate of the 
Knoevenagel condensation more stable, affording exclusively the thermodynamically more stable 
E-derivatives. Spectral and analytical data obtained for all new compounds are in accordance with 
those of the previously described counterparts [6-9], and support the assigned chemical structure. 
We finally synthesized a series of triazolo[4,5-b/c]pyridin-acrylonitrile derivatives, maintaining the 
same feature in the heterocyclic moiety, while the phenyl-moiety of the side chain was 
functionalized using a variety of groups chosen from those endowed with the most antiproliferative 
activity in the previous series (Br, CH3, OCH3, 3,4,5(OCH3)3), or totally substituted with a naphtyl 
moiety, as depicted in Figure 1. 
 
 
Figure 1. General chemical structures for the triazolo[4,5-b/c]pyridin-acrylonitrile derivatives synthesized in this work. 
 
All new derivatives were synthesized following a consolidated chemistry [9]. From each 
triazolopyridine intermediate (1a,b of Scheme 1), we obtained 3 series of E isomers from 
substitution on each of the N atoms (N1-3) of the triazole moiety (2-4a,b of Scheme 1). All 
compounds were evaluated for antiproliferative activity against a panel of cell lines derived from 
hematological and solid human tumors. To investigate whether the antiproliferative activities of the 
synthesized compounds were related to an interaction with tubulin, in vitro inhibition of tubulin 
polymerization was determined using a fluorescence-based assay. The preliminary determination of 
the dissociation constant Kd of the new compounds from tubulin was carried out in vitro by 
fluorescence spectroscopy. The values of Kd and the tubulin binding site were then confirmed for all 
compounds by isothermal titration calorimetry (ITC). Finally, a molecular modelling study was 
carried out to draw a molecular rationale for the binding of these new series of molecules to tubulin. 
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2. Chemistry 
The intermediate compound 3H-[1,2,3]triazolo[4,5-b]pyridine (1a) was commercially available 
while the 3H-[1,2,3]triazolo[4,5-c]pyridine (1b) was prepared in good yield via diazotation reaction 
with NaNO2 starting from the pyridine-3,4-diamine. The 3H-[1,2,3]triazolo[4,5-b/c]pyridine-1,2,3-
carbonitrile derivatives (2-4a,b) were in turn prepared by nucleophilic substitution reaction of 
triazolo derivatives (1a,b) with chloroacetonitrile in dimethylformamide (DMF) in the presence of 
triethylamine (Et3N) (Scheme 1), following a procedure reported in details in our previous work [9]. 
In particular the yields of the condensation of 1a and 1b with chloroacetonitrile afforded the 
mixture of compounds 2-4a, in 78 % in the ratio 2a (24%), 3a (16%), 4a (38%); and compounds 2-
4b, in 63 % in the ratio 2b (19%), 3b (16%), 4b (28%). 
 
 
Scheme 1: Synthesis of intermediate 3H-[1,2,3]triazolo[4,5-b/c]pyridine-1,2,3-carbonitrile (2-4a,b). 
 
Finally, the synthesis of triazolo[4,5-b/c]pyridin-acrylonitrile derivatives (6c-g, 7d-e, 8d-e, 9c-f, 
10d-e, 11d-e) was accomplished by Knoevenagel condensation of intermediates (2-4a,b) with the 
appropriate commercially available aldehydes (5c-g), in toluene at reflux in the presence of Et3N 
(Scheme 2) [6]. In this new series, between the two possible geometric isomers (E/Z), E-isomers 
were obtained as the sole product. Spectral and analytical data obtained for all new compounds 
were in accordance with those of previously described derivatives [6, 11, 12] and supported the 
assigned chemical structure. 
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Scheme 2: Synthesis of triazolo[4,5-b/c]pyridin-acrylonitrile derivatives 6c-g, 7d-e, 8d-e, 9c-f, 10d-e and 11d-e. 
 
3. In vitro cell growth inhibition assay 
To characterize the tumor cell growth inhibitory profile of all new synthesized compounds 6c-g, 7d-
e, 8d-e, 9c-f, 10d-e and 11d-e, their antiproliferative activity against a panel of 9 cell lines derived 
from different human tumors was evaluated (Table 1). From these data, a structure-activity 
relationship could be established based on the variation of the position of the pyridine N atom, and 
of the nature and position of the substituent R on the molecular scaffold (Scheme 1). As can be seen 
by comparing corresponding data for (6-8) and (9-11) molecular series, the position of the pyridine 
N atom only marginally affects the activity of the relevant compounds, those belonging to the 6-8  
series being slightly more active than the corresponding 9-11 derivatives (e.g., compare EC50(6e) = 
10.3 - 36.8 µM and EC50 (9e) = 13.3 – 41.4 µM, Table 1). On the contrary, for both compound 
series (6-8) and (9-11) the presence of the R substituent either at position 1 or 3 of the triazole ring 
provides better antiproliferative activity with respect to those carrying R at position 2 in all cell 
lines. Thus, taking the HeLa cell line as a proof-of-concept, the range of EC50 values for compound 
6d (0.97 µM, Table 1), featuring the substituent R = 4-CH3-C6H4 at position 1, are significantly 
lower than those of the corresponding isomer 7d (25.1 µM, Table 1), in which the same R locates at 
position 2 of the triazole ring. Also, the derivatives featuring bulkier Rs at positions 1 of 
triazolo[4,5-b]pyridine and ]triazolo[4,5-c]pyridin derivatives, i.e., 2-naphtyl (6f, EC50 = 17.2 µM 
and 9f, EC50 = 22.2 µM) and 3,4,5-(CH3O)-C6H2 (6g, EC50 = 13.8 µM) show significantly lower 
potency with respect to all other compounds bearing less sterically hindered groups at the same sites 
(Table 1).  
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Table 1. Half-maximal inhibitory concentration (EC50, µM) of compounds (6-8) and (9-11) in different human cancer 
cell lines. EC50 values are the means of three independent determinations. 
Cpd Pos. 
"N" R 
aHeLa bDU145 
cCCRF-
CEM 
dMCF-7 eA-427 
fLCLC 
103H 
gDAN-G h5637 iHL-60 
6c 1 4-Br-C6H4 
0.65 
± 0.14 
0.98 
 ± 0.31 
0.76 
 ± 0.15 
7.1 
 ± 0.7 
1.2 
 ± 0.6 
2.1 
 ± 0.4 
15.4 
 ± 2.2 
1.9 
 ± 0.6 
12.2 
 ± 1.9 
6d 1 4-CH3-C6H4 
0.97 
 ± 0.23 
1.4 
 ± 0.6 
0.99 
 ± 0.18 
10.9 
 ± 2.1 
1.6 
 ± 0.6 
1.9 
 ± 0.2 
18.9 
 ± 2.1 
2.2 
 ± 0.5 
10.9 
 ± 1.3 
6e 1 4-CH3O-C6H4 
10.3 
 ± 1.2 
12.7 
 ± 2.2 
7.4 
 ± 0.6 
25.6 
 ± 1.3 
8.9 
 ± 0.4 
10.2 
 ± 1.0 
36.8 
 ± 2.3 
12.6 
 ± 1.8 
27.9 
 ± 2.0 
6f 1 2-Naphtyl 17.2 
 ± 1.9 
39.2 
 ± 1.7 
15.6 
 ± 2.2 
59.8 
 ± 2.6 
17.4 
 ± 1.1 
17.1 
 ± 1.3 
78.3 
 ± 3.4 
19.4 
 ± 1.2 
68.3 
 ± 2.8 
6g 1 
3,4,5-
(CH3O)3-
C6H2 
13.8 
 ± 1.4 
15.8 
 ± 1.5 
11.3 
 ± 1.6 
29.1 
 ± 1.8 
11.6 
 ± 1.0 
13.8 
 ± 1.1 
40.1 
 ± 2.8 
12.5 
 ± 1.1 
37.1 
 ± 1.6 
7d 2 4-CH3-C6H4 
25.1 
 ± 2.3 
22.4 
 ± 1.9 
32.6 
 ± 2.3 
48.5 
 ± 2.0 
39.6 
 ± 1.6 
37.5 
 ± 1.9 
88.1 
 ± 4.2 
33.1 
 ± 1.7 
78.3 
 ± 3.1 
7e 2 4-CH3O-C6H4 
38.6 
 ± 2.5 
31.6 
 ± 1.8 
33.7 
 ± 1.7 
67.8 
 ± 2.4 
45.8 
 ± 1.3 
51.4 
 ± 2.2 
90.6 
 ± 3.9 
49.2 
 ± 2.3 
69.5 
 ± 2.9 
8d 3 4-CH3-C6H4 
3.3 
 ± 0.8 
2.7 
 ± 1.1 
1.8 
 ± 0.5 
15.4 
 ± 1.9 
3.9 
 ± 0.2 
2.2 
 ± 0.3 
26.7 
 ± 1.5 
4.8 
 ± 0.3 
31.1 
 ± 2.2 
8e 3 4-CH3O-C6H4 
11.1 
 ± 1.3 
12.6 
 ± 1.4 
8.5 
 ± 0.9 
31.0 
 ± 2.3 
10.7 
 ± 1.8 
12.6 
 ± 1.5 
49.8 
 ± 2.0 
15.3 
 ± 1.2 
49.9 
 ± 2.4 
Cpd Pos. 
"N" R 
aHeLa bDU145 
cCCRF-
CEM 
dMCF-7 eA-427 
fLCLC 
103H 
gDAN-G h5637 iHL-60 
9c 1 4-Br-C6H4 
1.6 
 ± 0.8 
1.2 
 ± 0.3 
1.2 
 ± 0.3 
8.5 
 ± 0.4 
2.8 
 ± 0.8 
3.2 
 ± 0.7 
20.0 
 ± 2.6 
2.9 
 ± 0.2 
17.5 
 ± 2.2 
9d 1 4-CH3-C6H4 
2.3 
 ± 0.3 
2.8 
 ± 0.4 
2.5 
 ± 0.2 
14.4 
 ± 1.9 
3.5 
 ± 0.6 
4.1 
 ± 0.4 
19.2 
 ± 2.2 
3.3 
 ± 0.4 
18.6 
 ± 2.0 
9e 1 4-CH3O-C6H4 
13.1 
 ± 1.6 
13.8 
 ± 1.9 
9.9 
 ± 0.7 
29.5 
 ± 1.8 
10.1 
 ± 1.0 
12.9 
 ± 1.1 
41.4 
 ± 2.5 
17.1 
 ± 1.5 
32.9 
 ± 2.1 
9f 1 2-Naphtyl 22.2 
 ± 1.4 
36.7 
 ± 1.5 
22.1 
 ± 1.8 
68.6 
 ± 2.2 
24.4 
 ± 1.3 
27.1 
 ± 1.7 
81.5 
 ± 2.9 
23.6 
 ± 1.7 
70.5 
 ± 2.2 
10d 2 4-CH3-C6H4 
32.0 
 ± 2.6 
33.7 
 ± 1.8 
30.2 
 ± 2.1 
44.8 
 ± 2.9 
41.2 
 ± 2.1 
41.5 
 ± 1.8 
90.9 
 ± 3.9 
35.2 
 ± 1.1 
85.1 
 ± 3.6 
10e 2 4-CH3O-C6H4 
44.1 
 ± 2.7 
41.1 
 ± 2.2 
43.6 
 ± 2.0 
77.3 
 ± 2.7 
52.1 
 ± 2.8 
57.7 
 ± 3.0 
98.8 
 ± 3.1 
50.6 
 ± 2.1 
72.8 
 ± 3.1 
11d 3 4-CH3-C6H4 
9.5 
 ± 1.1 
8.2 
 ± 1.6 
7.8 
 ± 0.3 
28.2 
 ± 2.1 
9.9 
 ± 1.1 
7.5 
 ± 0.9 
41.4 
 ± 1.8 
10.6 
 ± 1.2 
39.3 
 ± 2.5 
11e 3 4-CH3O-C6H4 
17.6 
 ± 1.7 
15.8 
 ± 1.2 
16.3 
 ± 1.1 
38.6 
 ± 3.0 
17.7 
 ± 2.2 
16.9 
 ± 1.8 
57.2 
 ± 2.6 
20.1 
 ± 2.1 
59.3 
 ± 2.8 
Colchicinej - 0.027 
± 0.003 
0.018 
± 0.002 
0.021 
± 0.003 
0.061 
± 0.005 
0.045 
± 0.001 
0.070 
± 0.005 
0.059 
± 0.006 
0.053 
± 0.009 
0.0086 
± 0.008 
aHeLa = ACC-57 (cervix carcinoma); bDU145 = ACC-261 (prostate carcinoma); cCCRF-CEM = ACC-240 (T-cell leukemia); dMCF-
7 = ACC-115 (breast adenocarcinoma); eA-427 = ACC-234 (small cell lung carcinoma); fLCLC 103H = ACC-384 (large cell lung 
carcinoma); gDAN-G = ACC-249 (pancreas carcinoma); h5637 = ACC-35 (urinary bladder carcinoma); iHL-60 = ACC-3 (acute 
myeloid leukemia); jColchicine = reference compound. 
 
Within the entire pool of synthesized molecules, compound 6c in which R = 4-Br-C6H4 was found 
to be the most potent antiproliferative agent, with EC50 values in the range 0.65-15.4 µM towards 
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all cell lines. In detail, compound 6c inhibited the growth of HeLa cells with a half-maximal 
inhibitory concentration EC50 = 0.65 ± 0.14 µM (Figure 2A). Similarly, inhibition of DU145 and 
CCRF-CEM cell growth was achieved by the same compound with EC50 of 0.98 ± 0.31 and 0.76 ± 
0.15 µM, respectively. Good antiproliferative activity for 6c was also observed against breast 
(MCF-7), small (A-427)/non small (LCLC 103H) cell lung, and urinary bladder (5637) carcinoma 
cell lines (Table 1), whilst moderate activity (10 -20 µM) was recorded in the case of acute myeloid 
leukemia (HL-60) and pancreatic carcinoma cell lines (DAN-G, Figure 2B). 
 
Figure 2. Compound 6c inhibition of proliferation of HeLa (A) and DAN-G (B) cells. 
  
 
Nonspecific cytotoxicity of anticancer drugs may constitute a major obstacle in cancer 
chemotherapy. Accordingly, we also preliminarily determined the effect of the two most promising 
compounds, 6c and 6d, on the proliferation activity of three normal cell lines (i.e., human peripheral 
mononuclear blood cells (HPMBC), human pulmonary fibroblasts (HPF), and human prostate 
epithelial cells (HPEC), Table S1). Comparison of the relevant EC50 values with those of the 
pertinent malignant cell lines (Table 1) reveals that both compounds are endowed - on average – 
with substantial less normal cell cytotoxicity (28.5-35 x for HPEC, 14-17 x for HPF, and 40-55 x 
for HPEC, respectively). 
 
4. In vitro tubulin polymerization assay 
To investigate whether the antiproliferative activities of compounds (6-8) and (9-11) were related to 
an interaction with tubulin, they were assayed for their inhibitory effects on tubulin polymerization 
(ITP) in vitro using a fluorescence-based tubulin polymerization assay. As shown in Figure 3, the 
hit compound 6c was able to inhibit the rate and extent of tubulin assembly in a concentration-
dependent manner, the half-maximal inhibition (ITP IC50) occurring at 17.2 ± 0.9 µM.  
 
Figure 3. (A) In vitro concentration-dependent inhibition of tubulin polymerization by compound 6c (ITP IC50 = 17.2 ± 
0.9 µM). Symbol legend: , 0 µM; , 5 µM; ▲, 10 µM; , 15 µM; , 20 µM; , 30 µM; , 40 µM. (B) 
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Determination of 6c ITP IC50 value by sigmoidal fitting of steady state levels of tubulin assembly from panel A vs. drug 
concentration. Three independent sets of experiments were performed; however, only one of the sets is shown for 
clarity. 
 
 
 
Compounds 6d was also found to inhibit tubulin assembly with an ITP IC50 of 23.9 ± 1.2 µM. In the 
(9-11) series, only compound 9c was endowed with appreciable tubulin depolymerization activity, 
with ITP IC50 = 29.1 ± 1.5 µM. Under similar conditions, four reference compounds - colchicine, 
nocodazole, podophyllotoxin, and vinblastine sulfate - exhibited significantly more potent 
microtubule depolymerization activity, with ITP IC50 of 1.32 ± 0.23, 0.81 ± 0.07, 0.26 ± 0.09, and 
0.15 ± 0.07 µM, respectively. Accordingly, compounds 6c, 6d, and 9c can be classified as moderate 
tubulin polymerization inhibitors. Of note, we observe that the determined concentrations required 
to inhibit tubulin polymerization by these three compounds are much higher than those required for 
cytotoxicity, a phenomenon however well documented in the literature [see, for instance, 13-16]. 
All other compounds had ITP IC50 values > 30 µM; as such, they were regarded to have only weak 
activity as inhibitors of tubulin polymerization.  
Tubulin polymerization inhibitors usually interfere with the G2/M phase of the cell cycle by altering 
the dynamics of tubulin polymerization, ultimately triggering cell death via apoptotic pathways. 
Therefore, we considered interesting to study the effect exerted by the two lead compounds, 6c and 
6d, on cell cycle progression by flow cytometry experiments (Figure S2). The results show that 
untreated (control) prostate carcinoma cells DU145, taken as a proof-of-concept, distributed in the 
Sub-G1 (8.7%), G0/G1 (78%), S (3.6%), and G2/M (9.5%) phase. On the other hand, both 
compounds arrested most of the cells in the G2/M phase (71.1% and 69.3% for 6c and 6d, 
respectively, Figure S2). Collectively, these results are consistent with the indication that these 
molecules can act as efficient mitotic blockers. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5. Preliminary determination of the dissociation constant of compounds 6c to tubulin in vitro 
by fluorescence spectroscopy 
According to the results presented above, 6c was able to prevent the assembly of tubulin with ITP 
EC50 < 20 µM.  Therefore, we performed a preliminary investigation to determine whether 6c 
directly interacted with tubulin. Compound 6c quenched the tryptophan fluorescence of tubulin in a 
concentration-dependent fashion, thereby confirming the interaction between the small molecule 
and the protein (Figure 4A).  
 
Figure 4. (A) Quenching of intrinsic tryptophan fluorescence of tubulin by different concnetrations of compound 6c. 
Symbol legend: , 0 µM; , 5 µM; ▲, 10 µM; , 15 µM; , 20 µM; , 30 µM; , 40 µM. Tubulin concentration = 
2 µM. (B) Differential change in fluorescence intensity of tubulin upon binding of compound 6c. Three independent 
sets of experiments were performed; however, only one of the sets is shown for clarity. 
 
 
 
The dissociation constant (Kd) of compound 6c from tubulin - obtained by fitting the maximum 
tubulin fluorescence intensity change as a function of compound concentration (Figure 4B) - was 
found to be equal to 19.6 ± 1.0 µM. Based on this preliminary information and with the twofold 
purpose of obtaining 1) accurate Kd values for all compounds and 2) a full thermodynamic 
characterization of compound/tubulin interactions (indispensible for validation of the modeling 
results, vide infra), further binding studies were conducted by ITC. 
 
6. Determination of the dissociation constant and tubulin binding site of compounds (6-8) 
and (9-11) by Isothermal Titration Calorimetry (ITC) 
In order to investigate the tubulin binding affinities of all (6-8) and (9-11) compounds in detail, 
thermodynamic studies were conducted using isothermal titration calorimetry (ITC). The averaged 
dissociation constant (Kd), binding free energy (∆Gb), enthalpy (∆Hb) and entropy terms (-T∆Sb) 
resulting from three independent ITC measurements on each compound are listed in Table 2, while 
Figure 5 displays some representative ITC results and fitting curves for compounds belonging to 
both (6-8) and (9-11) series. 
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Table 2. ITC determined thermodynamic data of compounds (6-8) and (9-11) binding to tubulin. ∆Gb = ∆Hb –T∆Sb. 
∆Gb = RT lnKd. n = number of binding site. All experiments were run in triplicate. Errors on ∆Hb are within 5%. 
Cpd Pos. 
"N" R Kd (µM) ∆Gb (kcal/mol) ∆Hb (kcal/mol) 
T∆Sb 
(kcal/mol) n (-) 
6c 1 4-Br-C6H4 16.4 -6.75 -9.21 2.46 0.98 
6d 1 4-CH3-C6H4 22.0 -6.57 -8.96 2.39 1.00 
6e 1 4-CH3O-C6H4 192 -5.24 -7.35 2.11 0.95 
6f 1 2-Naphtyl 385 -4.82 -6.87 2.05 0.97 
6g 1 3,4,5-(CH3O)3-C6H2 241 -5.10 -7.16 2.06 1.01 
7d 2 4-CH3-C6H4 581 -4.56 -6.81 2.25 0.96 
7e 2 4-CH3O-C6H4 763 -4.40 -6.75 2.35 1.02 
8d 3 4-CH3-C6H4 58.4 -5.97 -7.84 1.87 0.98 
8e 3 4-CH3O-C6H4 217 -5.17 -7.23 2.06 0.99 
Cpd Pos. 
"N" R Kd (µM) ∆Gb (kcal/mol) ∆Hb (kcal/mol) 
T∆Sb 
(kcal/mol) n (-) 
9c 1 4-Br-C6H4 33.9 -6.30 -8.63 2.33 1.00 
9d 1 4-CH3-C6H4 64.5 -5.91 -7.79 1.88 0.97 
9e 1 4-CH3O-C6H4 246 -5.09 -7.13 2.03 0.97 
9g 1 2-Naphtyl 376 -4.83 -6.91 2.08 0.96 
10d 2 4-CH3-C6H4 554 -4.59 -6.75 2.16 1.03 
10e 2 4-CH3O-C6H4 749 -4.41 -6.59 2.18 0.99 
11d 3 4-CH3-C6H4 175 -5.29 -7.41 2.12 0.95 
11e 3 4-CH3O-C6H4 283 -5.00 -6.98 1.98 0.98 
colchicine  0.058 -10.21 -11.80 1.59 1.01 
 
Figure 5. Representative ITC binding isotherms for 6c (A), 6f (B), 7e (C), 9c (D), 9f (E), and 10e (F) titrations into 
tubulin solutions. Panel A, insert: example of ITC raw data. 
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For the two series of compounds, the interaction with tubulin resulted in an exothermic ligand-
binding event, with Kd values in the range 16.4 - 763 µM and 33.6 - 749 µM for the (6-8) and (9-
11) compounds, respectively.  Importantly, the ITC-derived Kd value for compound 6c (16.4 µM) is 
nicely in agreement with the value obtained from the corresponding tubulin fluorescence quenching 
experiment (19.6 ± 1.0 µM). Generally speaking, the tubulin-compound binding is driven by the 
simultaneous participation of stabilizing van der Waals and hydrophobic interactions (∆Hb < 0), 
while entropy slightly disfavor complex formation (T∆Sb > 0). The conformational entropy change 
is commonly unfavorable in protein-ligand binding event, as the binding process involves the loss 
of configurational degrees of freedom for both the drug molecule and the protein, resulting in an 
ultimate negative change in conformational entropy. However, the presence of the planar bicyclic 
scaffold characterizing all present compounds confers a degree of overall molecular rigidity, which 
reflects only in a confined, unfavorable entropic contribution to ligand binding. 
The last row in Table 2 shows the binding thermodynamic parameters for colchicine, used as a 
reference compound. The corresponding Kd value of 58 nM, in line with previous findings, confirm 
that all title compounds were consistently weaker than colchicine in their interaction with tubulin. 
To understand whether the cytotoxic effect of the present (6-8) and (9-11) derivatives is dependent 
on their antimicrotubule activity, we next examined the relationship between the Kd values 
determined by the ITC tubulin binding assay and EC50 values in the cell-based assays. Since 
cytotoxicity tests were performed on 9 different human tumor cell lines, for the purpose of this 
comparison a single EC50,av value, corresponding to half-maximal inhibitory concentration value 
averaged over all cell lines, was employed. As shown in Figure 6, the resulting average EC50 vs. Kd 
plot show a highly positive correlation (R2 = 0.980), suggesting a strong correlation between (6-8) 
and (9-11) compounds tubulin binding and cytotoxic potency. Therefore, we could conclude that 
the cytotoxic activity of both (6-8) and (9-11) derivatives is largely attributed to their 
antimicrotubule action. 
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Figure 6. Correlation between tubilin binding activity (Kd) and average cytotoxic activity (EC50,av) of compounds (6-8) 
() and (9-11) (▲). 
 
 
Microtubule-destabilizing compounds often bind tubulin by nesting into specific binding sites. In a 
previous work [8] we assessed the capability of a series of related compounds to compete with 
colchicine or paclitaxel for binding to tubulin by resorting to a competitive scintillation proximity 
assay. According to that study [8], we found that those compounds competitively inhibited 
[3H]colchicine binding to biotinylated tubulin  while they did not compete with [3H]paclitaxel. In 
this work, however, we resorted again to ITC to examine whether the present compounds do 
compete either with colchicine or paclitaxel for the respective binding sites. With respect to the 
competitive scintillation proximity assay, the ITC-based experiments offers several advantages, 
including a clear determination of eventual binding site competition and, above all, to avoid 
working with radioligands. 
Accordingly, we investigated the binding of compound 6c to purified tubulin in the presence of 
colchicine or paclitaxel using ITC. Panel A of Figure 7 shows the typical exothermic profiles 
obtained for tubulin titration by 6c at 37°C either in the presence of colchicine (thick black data) or 
in the presence of paclitaxel (light gray data). Figure 7 B shows the corresponding binding 
isotherms, i.e. the integrated heats of reaction as a function of the 6c/tubulin molar ratio, in these 
two conditions.  
 
Figure 7. A: ITC raw data obtained by titrating 6c into a solution containing tubulin in the presence of colchicine (thick 
black curve) or paclitaxel (light gray curve). B: corresponding integrated heats of reaction in the presence of colchicine 
() or in the presence of paclitaxel ().  
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As can be easily seen from Figure 7B, in the presence of colchicine the tubulin binding of 6c is 
completely abrogated. Colchicine is a very tight tubulin binder, with Kd = 58 nM (Table 2). 
Accordingly, 6c (Kd = 16.4 µM) it is not able to displace colchicine from its tubulin binding site, as 
expected. Moreover, the fact that the titration of the tubulin-colchicine complex with 6c returned a 
completely flat curve is a clear indication that, upon saturation of all tubulin binding sites by 
colchicine, 6c is no longer able to interact with the protein, i.e., 6c binds tubulin at the colchicine 
binding site. On the contrary, the binding isotherm resulting from the titration of tubulin by 6c in 
the presence of paclitaxel (Figure 6B, circles) is practically coincident with that obtained in its 
absence (Figure 4A). Accordingly, 6c does not interact with tubulin by binding at the paclitaxel 
binding pocket. 
 
7. Molecular modeling rationale for the binding of compounds (6-8) and (9-11) to tubulin 
In order to determine the structural basis of the biological results discussed above, the binding 
ability of the synthesized compounds to the colchicine binding site of α,β-tubulin was investigated 
using a consolidated molecular modeling procedure based on the combination of docking and 
Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA)-based scoring techniques. 
Specifically, for this analysis we considered a subset of 3 compounds for each series, namely 6c, 6f, 
7e, 9c, 9f, and 10e, as representative of strong, moderate, and weak tubulin binders, respectively 
(Table 2 and Figure 5). Table 3 reports the results of this in silico analysis. As seen by comparing 
the entries in Tables 2 and 3, all ligands are correctly ranked for affinity, the magnitudes of the 
calculated ∆Gb,calc (and of the corresponding Kd,calc) values being in excellent agreement with those 
determined experimentally. 
 
Table 3. In silico binding thermodynamics of a subset of compounds (6-8) and (9-11) on human tubulin. The calculated 
value for colchicine is also reported for comparison. 
Cpd Pos. "N" R Kd,calc (µM) ∆Gb,calc (kcal/mol) ∆Hb,calc (kcal/mol) T∆Sb,calc (kcal/mol) 
6c 1 4-Br-C6H4 17.8 -6.70 ± 0.27 -23.07± 0.15 16.37 ± 0.23 
6f 1 2-Naphtyl 371 -4.84 ± 0.24 -18.88 ± 0.11 14.04 ± 0.21 
7e 2 4-CH3O-C6H4 635 -4.51 ± 0.23 -18.09 ± 0.13 13.58 ± 0.19 
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Cpd Pos. "N" R Kd,calc (µM) ∆Gb,calc (kcal/mol) ∆Hb,calc (kcal/mol) T∆Sb,calc (kcal/mol) 
9c 1 4-Br-C6H4 37.3 -6.24 ± 0.19 -22.16 ± 0.12 15.92± 0.15 
9f 1 2-Naphtyl 436 -4.74 ± 0.26 -18.57 ± 0.13 13.83 ± 0.23 
10e 2 4-CH3O-C6H4 798 -4.37 ± 0.25 -17.23 ± 0.11 12.86 ± 0.22 
colchicine  0.067 -10.12± 0.22 -24.11± 0.12 13.99 ± 0.18 
 
It is interesting to observe that, with respect to the experimental values (Table 2), both ∆Hb,calc and –
T∆Sb,calc are substantially overestimated by the MM/PBSA calculations (Table 3); yet, since a 
parallel shift is observed between experimental and computed ∆H and –T∆S, (see Figure S1) their 
difference (i.e., ∆Gb,calc) is ultimately close to the relevant experimental value (∆Gb). 
Concerning the binding mode of these new acrylonitrile derivatives, it has to be noticed that all 
compounds are provided with the chemical functions required for mapping the 3D pharmacophore 
model previously developed for tubulin inhibitors with a similar scaffold [8]. Indeed, taking the new 
lead compound 6c as a meaningful example, all pharmacophore elements could be easily fitted by 
the proper molecular features, as shown in Figure 8A. Specifically, the triazolopyridinyl ring 
matches both the hydrophobic aromatic (HYAr) and the first hydrogen bond acceptor (HBA) 
features, while the cyano nitrogen atom overlays the second HBA. Finally, the 4-Br-C6H4enyl 
substituent maps the ring aromatic (RA) feature, presenting the aromatic ring in the proper 
conformation to optimize this molecular requirement (Figure 8A). 
 
Figure 8. A: Mapping of compound 6c onto the 3D pharmacophore model developed for structurally-related tubulin 
inhibitors [8]. The 3D pharmacophoric hypothesis features are portrayed as meshed spheres, color-coded as follows: 
light green, HBA; light blue, HYAr; light orange, RA. Compound 6c is shown as atom-colored sticks-and-balls (gray, 
C; blue, N; dark red, Br; white, H). B: Equilibrated MD snapshots of tubulin/6c complex. The image is a zoomed view 
of the binding site. The ligand is portrayed as in panel A, while the protein residues mainly involved in the interaction 
with 6c are highlighted as colored sticks and labelled. H-bonds interactions are shown as dotted black lines. Hydrogen 
atoms, water molecules, and ions are omitted for clarity.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Our Molecular Dynamics (MD) simulations that allowed us to give a precise description of the 
binding mode of these new compounds have confirmed this interactions pattern. In fact, its 
combination with the relevant per-residue decomposition analysis of the binding enthalpy (∆Hres) 
provided both the identification of the tubulin residues mainly involved in ligand binding and the 
nature underlying each specific interaction (Figure 8B and Figure 9A). 
 
Figure 9. A: Comparison of the per-residue binding enthalpy decomposition (∆Hres) for compounds 6c and 7e in 
complex with tubulin. Only those amino acids critical for the binding are shown. B: Superposition of equilibrated 
binding pose of 6c (purple) and 7e (red) in the tubulin binding cavity. 
 
 
As can be seen in Figure 8B, the p-bromophenyl ring of 6c is perfectly encased in the protein 
binding pocket lined by residues βL242, βL248, βA250, βl252, βK254 and βL255, and the deriving 
hydrophobic stabilizing interactions provided an overall contribution of -5.01 kcal/mol to the 
binding (Figure 9A). Furthermore, the donor guanidinium group of βK352 on the receptor finds its 
acceptor counterpart in the triazole N3 of the inhibitor, forming a persistent hydrogen bond (average 
dynamic distances (ADL) = 2.1 ± 0.1 Å) which yields a corresponding stabilizing contribution of 
∆Hres = -2.26 kcal/mol. The triazolepyridinyl moiety is embedded in a hydrophobic pocket 
consisting of the side chains of αA180, αV181, βV257, βM259, and βV351 which all concur to 
foster a network of hydrophobic interactions with the ligands (∑∆Hres = -2.77 kcal/mol, Figure 9A). 
Finally, the cyano N atom is engaged in a permanent hydrogen bond with the hydroxyl group of the 
side chain of βT314 (ADL = 2.3 ± 0.2 Å;  ∆Hres = -1.98 kcal/mol). 
The same analysis applied to the other tested compounds, allowed us to confirm the structure-
activity relationship proposed above (based on the in vitro results), and the related experimental 
data. First, all compounds demonstrated similar binding modes within the same tubulin binding 
pocket, the position of the substituted acrylonitrile moiety with respect to the triazolpyridinyl ring 
(N1, N2, or N3) modulating their protein binding affinity. Indeed, compounds featuring 
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substitutions at the N1 position are endowed with the highest tubulin affinity; yet, substitutions at 
position N3 is also well tolerated, the pyridine nitrogen atom not being involved in any specific 
interaction. On the other hand, compound 7e (taken as a representative example of the N2 
substituted derivatives) exhibits a substantially lower affinity compared to e.g., 6c, as the 
conformation it assumes in the tubulin binding site (Figure 9B) does not satisfy all molecular 
determinants requested by the pharmacophore model. Specifically, the orientation of the chemical 
groups of 7e involved in hydrogen bonds with tubulin residues βT314 and βK352 leads to a weaker 
interactions both in terms of dynamics stability (ADL = 2.8 ± 0.1 Å and ADL = 2.7 ± 0.3 Å for 
βT314 and βK352, respectively) and enthalpic contribution (∆HβT315 = -1.55 kcal/mol and 
∆HβK252 = -1.77 kcal/mol, Figure 9A). This, in turn, locally reflects into a sub-optimal 
encasement of 7e in both protein hydrophobic pockets (thereby resulting into a lower stabilization 
energy of the protein residues directly involved in such specific interactions (Figure 9A), and 
globally into a less favorable ∆Gb,calc value for this  molecule (Table 3). 
 
8. Conclusions 
In this work we presented the synthesis and in vitro anticancer activity of a new series of E isomers 
of triazolo[4,5-b/c]pyridin-acrylonitrile derivatives (6c-g, 7d-e, 8d-e, 9c-f, 10d-e, 11d-e). All 
compounds were found to exert moderate to interesting antiproliferative activities against 9 
different cancel cell lines derived from solid and hematological human tumors. Fluorescence-based 
assays proved that these molecules interfere with tubulin polymerization, and isothermal titration 
calorimetry led to full tubulin/compound binding thermodynamics determination (i.e., Kd, ∆Gb, 
∆Hb, and Τ∆Sβ values). Coupling all experimental information with in silico modelling of the 
interactions between tubulin and the title compounds allowed to conclude that the position of the 
pyridine nitrogen atom does not exert a significant influence on their binding affinity toward their 
target protein. On the contrary, the position of the different R substituents on the three N atoms of 
the triazole ring is the major molecular determinant for the biological activity of these molecules, 
the N1 and N3 position leading to more potent compounds with respect to those presenting the 
same Rs at the N2 position. 
 
9. Experimental section 
9.1. Synthetic methods 
Melting points were determined by a Kofler hot stage or Digital Electrothermal apparatus, and are 
uncorrected. 1H and 13C-NMR spectra were recorded on a Varian XL-200 and on a Bruker Avance 
III 400 NanoBay instruments, using TGC-MS as internal standard. The chemical shift values are 
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reported in ppm (δ) and coupling constants (J) in Hertz (Hz). Signal multiplicities are represented 
by: s (singlet), d (doublet) and m (multiplet). GC/MS spectra were performed on combined HP 
5790 GC/MS and on a triple quadrupole (API 2000, Applied Biosystem MDS SCIEX) apparatuses. 
Column chromatography was performed using 230-400 mesh silica gel (Merck silica gel 60). Light 
petroleum refers to the fraction with b.p. 40-60 °C. The analytical results for C, H, N and chlorine 
were within 0.4% of the theoretical values. 
 
9.1.1. Starting materials, intermediates and known compounds 
3H-[1,2,3]triazolo[4,5-b]pyridine (1a), 3,4-diaminopyridine, aldehydes, 2-chloroacetonitrile, 
triethylamine, acetic acid, organic solvents and inorganic reagents were commercially available. 
3H-[1,2,3]triazolo[4,5-c]pyridine (1b) was prepared following a consolidated procedure [10]. 
 
9.1.1.1. 3H-[1,2,3]triazolo[4,5-c]pyridine (1b). Yield: 83%. M.p.: 81 °C. 1H-NMR (DMSO-d6): δ 
9.47(s, 1H, CH-4); 8.47(d, 1H, CH-7, J = 8 Hz); 7.88 (d,1H, CH-6, J = 4.2 Hz). 13C-NMR (CDCl3): 
δ 143.21 (C), 141.72 (CH), 138.56 (CH), 128.34 (C), 111.45 (CH). GC/MS: 121 (M+H). Anal. 
Calcd for (C5H4N4): C, 50.00; H, 3.36; N, 46.65. Found: C, 49.92; H, 3.27; N, 46.72. 
 
9.1.2. General procedure for the preparation of the intermediates 2a-b, 3a-b, 4a-b. 
2 g (16.6 mmol) of the appropriate 3H-[1,2,3]triazolo[4,5-b/c]pyridine (1a,b) were dissolved in 20 
ml of dimethylformamide (DMF). 1.95 g (19.4 mmol) 2.68 ml of triethylamine and 2 g (26.5 mmol) 
1.69 ml of chloroacetonitrile were added to the resultant solution. The whole mixture was heated 
under reflux for 12 h. After cooling, the triethylamine hydrochloride formed was filtered, and the 
solution was evaporated to dryness. The residue, dissolved in ether, was washes with water. 
Through evaporation of the extract, a residue containing the three isomers 2-4a or 2-4b was 
obtained. Isomers were separated by flash chromatography, elution with light petroleum-ethyl 
acetate 80:20 afforded desired compounds. 
 
9.1.2.1. 3H-[1,2,3]triazolo[4,5-b]pyridine-3-carbonitrile (2a). Yield: 24%. M.p.: 56.8-57 °C. 1H-
NMR (DMSO-d6): δ 8.86 (d, 1H, CH-5. J = 4.0 Hz); 8.66 (d, 1H, CH-7. J = 8.8 Hz); 7.61 (m, 1H, 
CH-6); 6.14 (s, 2H, CH2). 13C-NMR (CDCl3): δ 151.53 (CH); 144.76 (C); 136.18 (C); 129.18 (CH); 
120.96 (CH); 114.73 (C); 34. 27 (CH2). GC/MS: 146 (M+H). Anal. Calcd for (C6H3N5): C, 49.66; 
H, 2.08; N, 48.26. Found: C, 49.56; H, 2.19; N, 48.23. 
9.1.2.2. 2H-[1,2,3]triazolo[4,5-b]pyridine-2-carbonitrile (3a). Yield: 16%. M.p.: 98.6-100 °C. 1H-
NMR (DMSO-d6): δ 8.89 (d, 1H, CH-5, J = 4.0 Hz); 8.53 (d, 1H, CH-7, J = 8.8 Hz); 7.61-7.55 (m, 
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1H, CH-6); 6.34 (s, 2H, CH2). 13C-NMR (CDCl3): δ 155.15 (C); 153.21 (CH); 128.01 (C); 136.52 
(C); 127.57 (CH); 123.41(CH); 114.06 (C); 44.57 (CH2). GC/MS: 146 (M+H). Anal. Calcd for 
(C6H3N5): C, 49.66; H, 2.08; N, 48.26. Found: C, 49.61; H, 2.10; N, 48.18. 
9.1,2,3. 1H-[1,2,3]triazolo[4,5-b]pyridine-1-carbonitrile (4a). Yield: 38%. M.p.: 160-160.5 °C. 
1H-NMR (DMSO-d6): δ 8.80 (d, 1H, CH-5, J = 4 Hz); 8.50 (d, 1H, CH-7, J = 8.4); 7.74-7.70 (m, 
1H, CH-6); 6.22 (s, 2H, CH2). 13C-NMR (CDCl3): δ 156.54 (C); 148.89 (CH); 125.16 (C); 123.30 
(CH); 120.12 (CH); 114.79 (C); 36.38 (CH2). GC/MS: 146 (M+H). Anal. Calcd for (C6H3N5): C, 
49.66; H, 2.08; N, 48.26. Found: C, 49.59; H, 2.15; N, 48.24. 
9.1.2.4. 3H-[1,2,3]triazolo[4,5-c]pyridine-3-carbonitrile (2b). Yield: 19%. M.p.: 70-71 °C. 1H-
NMR (DMSO-d6): δ 9.50 (s, 1H, CH-4); 8.59 (d, 1H, CH-7,  J = 2.8 Hz); 8.17 (d, 1H, CH-6 J = 
6Hz); 6.30 (s, 2H, CH2). 13C-NMR (DMSO): δ 148.26 (C); 142.51 (CH); 136.06 (CH); 129.57 (C); 
114.70 (C); 112.90 (CH); 36.49 (CH2). GC/MS: 146 (M + H). Anal. Calcd for (C6H3N5): C, 49.66; 
H, 2.08; N, 48.26. Found: C, 49.61; H, 2.10; N, 48.29. 
9.1.2.5. 2H-[1,2,3]triazolo[4,5-c]pyridine-2-carbonitrile (3b). Yield: 16%. M.p.: 99-100 °C. 1H-
NMR (DMSO-d6): δ 9.58 (s, 1H, CH-4); 8.51 (d, 1H, CH-7, J = 6 Hz); 7.98 (d, 1H, CH-6, J = 6Hz); 
6.41 (s, 2H, CH2). 13C-NMR (DMSO): δ 146.14 (C); 145.61 (CH); 143.21 (CH); 141.22 (C); 113.91 
(C); 111.59 (CH); 44.55 (CH2). GC/MS: 146 (M + H). Anal. Calcd for (C6H3N5): C, 49.66; H, 2.08; 
N, 48.26. Found: C, 49.65; H, 2.03; N, 48.26. 
9.1.2.6. 1H-[1,2,3]triazolo[4,5-c]pyridine-1-carbonitrile (4b). Yield: 28%. M.p.: 80-81 °C. 1H-
NMR (DMSO-d6): δ 9.56 (s, 1H, CH-4); 8.68 (d, 1H, CH-7, J = 5.8 Hz); 8.01 (d, 1H, CH-6 J = 
4.6Hz); 6.21(s, 2H, CH2). 13C-NMR (DMSO): δ 145.39 (CH); 144.16 (CH); 142.30 (C); 136.10 (C); 
114.73 (C); 105.30 (CH); 33.51 (CH2). GC/MS: 146 (M + H). Anal. Calcd for (C6H3N5): C, 49.66; 
H, 2.08; N, 48.26. Found: C, 49.62; H, 2.04; N, 48.30. 
 
9.1.3. General procedure for the preparation of [1,2,3]triazolo[4,5-b/c]pyridin-acrylonitrile 
derivatives. 
To a solution of appropriate triazolo[4,5-b/c]pyridine-carbonitrile (2a-b, 3a-b, 4a-b) (1.4 mmol) 
and Et3N (4.0 mmol) in toluene (5 mL) stirred at room temperature, a solution of a selected 
aldehyde 5c-g (14 mmol) in the same solvent (3 mL) was added drop wise. The whole mixture was 
finally heated under reflux for 24 h. the solution was evaporated to obtain a crude residue 
containing a mixture of three E-isomers. The desired compounds were obtained by chromatography 
on silica gel column using light petroleum-ethyl acetate as eluent. 
9.1.3.1. (E)-2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-3-(4-bromophenyl)acrylonitrile (6c). 
Yield: 53%. M.p.: 174-175 °C. 1H-NMR (CDCl3): δ 8.87 (d, 1H, CH-5, J = 4.4 Hz); 8.38 (d, 1H, 
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CH-7, J = 8.0 Hz), 8.04 (s, 1H, CH); 7.80 (d, 2H, CH 2′-6′, J = 3.8 Hz); 7.70 (d, 2H, CH-3′-5′, J = 
3.8 Hz); 7.61 (m, 1H, CH-6). 13C-NMR (CDCl3): δ 157.85 (C); 149.31 (CH); 138.98 (CH); 132.83 
(2 CH); 130.99 (2 CH); 129.09 (C); 127.02 (C); 124.21 (C); 123.65 (CH); 119.45 (CH); 113.16 (C), 
106.68 (C). GC/MS: 326 (M+H). Anal. Calcd for (C14H8BrN5): C, 51.56; H, 2.47; Br, 24.50. 
Found: C, 51.60; H, 2.51; Br, 24.47. 
5.1.3.2. (E)-2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-3-(p-tolyl)acrylonitrile (6d). Yield: 53%. 
M.p. = 111-112 °C. 1H-NMR (DMSO-d6): δ 8.86 (d, 1H, CH-5. J = 4.4 Hz); 8.60 (d, 1H, CH-7. J = 
8.0 Hz), 8.27 (s, 1H, CH=); 7.91 (d, 2H, CH-2',6', J = 7.8 Hz); 7.78 (m, 1H, CH-6); 7.45 (d, 2H, 
CH-3′,5′, J = 7.8 Hz); 2.49 (s, 3H, CH3). 13C-NMR (CDCl3): δ 157.76 (C); 149.16 (CH); 144.82 
(C); 143.48 (CH); 130.21 (2 CH); 129.86 (2 CH); 127.44 (C); 124.33 (C); 123.46 (CH); 119.45 
(CH); 113.69 (C); 105.02 (C); 21.65 (CH3). GC/MS: 262 (M+H). Anal. Calcd for (C15H11N5): C, 
68.95; H, 4.24; N, 26.80. Found: C, 68.99; H, 4.26; N, 26.78. 
9.1.3.3. (E)-2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-3-(4-methoxyphenyl)acrylonitrile (6e). 
Yield: 35%. M.p. = 65.5-66 °C. 1H-NMR (DMSO-d6): δ 8.86 (d, 1H, CH-5. J = 4.0 Hz); 8.58 (d, 
1H, CH-7, J = 8.0 Hz), 8.23 (s, 1H, CH=); 7.80 (d, 2H, CH-2',6', J = 4.2 Hz); 7.76 (m, 1H, CH-6); 
7.20 (d, 2H, CH-3′,5′, J = 4.2 Hz); 7.18 (m, 1H, CH, J =4.2 Hz); 3.88 (s, 3H, CH3); 13C-NMR 
(CDCl3): δ 162.99 (C); 149.36 (CH); 141.29 (CH); 132.29 (2 CH); 131.71 (C); 124.40 (C); 123.25 
(CH); 122.73 (C); 119.65 (CH); 115.27 (2 CH); 114.08 (C); 103.22 (C); 55.64 (CH3). GC/MS: 278 
(M+H). Anal. Calcd for (C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 65.00; H, 4.03; N, 
25.24. 
9.1.3.4. (E)-2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-3-(naphthalen-2-yl)acrylonitrile (6f). 
Yield: 20%. M.p.: 186-187 °C. 1H-NMR (CDCl3): δ 8.87 (d, 1H, CH-5, J = 2.0 Hz); 8.41 (d, 1H, 
CH-7, J = 4.2 Hz); 8.34 (s, 1H, CH); 8.22 (s, 1H, CH-2′); 8.11 (d, 1H, CH-8′); 8.01-7.91 (m, 3H, 
napht); 7.66-7.60 (m, 3H, H-6 + 2H napht.). 13C-NMR (CDCl3): δ 157.85 (C); 149.24 (CH); 140.89 
(CH); 134.88 (C); 132.90 (C); 132.17 (CH); 129.44 (CH); 128.99 (CH); 128.64 (CH); 128.23 (CH); 
127.96 (CH); 127.67 (C); 127.39 (CH); 125.30 (C); 124.49 (CH); 123.54 (CH); 119.53 (CH); 
113.69 (C); 105.93 (C). GC/MS: 298 (M+H). Anal. Calcd for (C18H11N5): C, 72.72; H, 3.73; N, 
23.56. Found: C, 72.69; H, 3.88; N, 23.61.  
9.1.3.5. (E)-2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-3-(3,4,5-trimethoxyphenyl)acrylonitrile 
(6g). Yield: 35%. M.p.: 158-159 °C. 1H-NMR (CDCl3): δ 8.78 (d, 1H, CH-5. J = 8.4 Hz); 8.36 (d, 
1H, CH-7, J = 8.4 Hz), 7.97 (s, 1H, CH); 7.61 (m, 1H, CH-6); 7.27 (s, 2H, CH-2′,5′); 3.97 (s, 3H, 
CH3); 3.96 (s, 6H, 2 CH3). 13C-NMR (CDCl3): δ 157.72 (C); 153.56 (2 C); 149.19 (CH); 141.88 
(C); 141.22 (CH); 125.24 (C); 124.35 (C); 123.53 (CH); 119.44 (CH); 113.88 (C); 107.55 (2 CH); 
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104.83 (C); 61.15 (CH3); 56.36 (2 CH3). GC/MS: 338 (M+H). Anal. Calcd for (C17H15N5O3): C, 
60.53; H, 4.48; N, 20.76. Found: C, 60.57; H, 4.51; N, 20.74. 
9.1.3.6. (E)-2-(2H-[1,2,3]triazolo[4,5-b]pyridin-2-yl)-3-(p-tolyl)acrylonitrile (7d). Yield: 26 %. 
M.p.: 200-201 °C. 1H-NMR (CDCl3): δ 8.89 (d, 1H, CH-5, J = 2.6 Hz); 8.61 (s, 1H, CH); 8.31 (d, 
1H, CH-7, J = 8.6 Hz); 7.91 (d, 2H, CH-2′,6′, J = 8.8 Hz); 7.44-7.43 (m, 1H, CH-6); 7.34 (d, 2H, 
CH-3′,5′, J = 8.8 Hz); 2.45 (s, 3H, CH3). 13C-NMR (CDCl3): δ 155.61 (C); 153.84 (CH); 143.62 (2 
C); 138.89 (CH); 137.53 (C); 130.36 (2 CH); 130.19 (2 CH); 127.32 (CH); 123.47 (CH); 112.82 
(C); 111.15 (C); 21.80 (CH3). GC/MS: 262 (M+H). Anal. Calcd for (C15H11N5): C, 68.95; H, 4.24; 
N, 26.80. Found: C, 68.99; H, 4.20; N, 26.83. 
9.1.3.7. (E)-2-(2H-[1,2,3]triazolo[4,5-b]pyridin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (7e). 
Yield: 27 %. M.P.: 160-162 °C. 1H-NMR (DMSO-d6): δ 8.93 (d, 1H, CH-5, J = 2.6 Hz); 8.76 (s, 1H, 
CH=); 8.56 (d, 1H, CH-7, J = 8.6 Hz); 8.11 (d, 2H, CH-2′,6′, J = 8.8 Hz); 7.62 (m, 1H, CH-6); 7.22 
(d, 2H, CH-3′,5′, J = 8.8 Hz); 3.88 (s, 3H, CH3). 13C-NMR (CDCl3): δ 163.09 (C); 154.25 (CH); 
142.95 (C); 138.57 (CH); 137.60 (C); 132.88 (2 CH); 127.23 (CH); 123.80 (CH); 123.31 (C); 
115.31 (2 CH); 113.21 (C); 109.61 (C); 55.63 (CH3). GC/MS: 278 (M+H). Anal. Calcd for 
(C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 64.01; H, 4.03; N, 25.22. 
9.1.3.8. (E)-2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3-(p-tolyl)acrylonitrile (8d). Yield: 53%. 
M.p. = 95-96 °C. 1H-NMR (DMSO-d6): δ 8.96 (d, 1H, CH-5. J = 4.4 Hz); 8.81 (d, 1H, CH-7, J = 
8.6 Hz), 8.59 (s, 1H, CH); 7.94 (d, 2H, CH-2',6', J = 8.2 Hz); 7.7 (m, 1H, CH-6, J = 4.4 Hz, J = 8.6 
Hz); 7.4 (d, 2H, CH-3',5', J = 8.2 Hz); 2.46 (s, 3H, CH3). 13C-NMR (CDCl3): δ 151.03 (CH); 144.16 
(C); 142.71 (C); 139.38 (CH); 137.66 (C); 130.13 (2 CH); 130.01 (2 CH); 129.84 (CH); 127.85 (C); 
120.94 (CH); 113.45 (C); 105.76 (C); 21.72 (CH3). GC-MS: 262 (M+H). Anal. Calcd for 
(C15H11N5): C, 68.95; H, 4.24; N, 26.80. Found: C, 68.98; H, 4.21; N, 26.83. 
9.1.3.9. (E)-2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3-(4-methoxyphenyl)acrylonitrile (8e). 
Yield: 28%. M.p.: 144-145 °C. 1H-NMR (DMSO-d6): δ 8.91 (d, 1H, CH-5, J = 4.9 Hz); 8.76 (d, 1H, 
CH-7, J = 8.2 Hz), 8.45 (s, 1H, CH=); 7.99 (d, 2H, CH-2',6', J = 8.0 Hz); 7.68 (m, 1H, CH-6); 7.19 
(d, 2H, CH-3',5', J = 8.0 Hz); 3.88 (s, 3H, CH3). 13C-NMR (CHCl3): δ 162.70 (C); 151.93 (CH); 
145.18 (C); 139.67 (CH); 137.57 (C); 131.92 (2 CH); 129.37 (CH); 123.12 (C); 120.84 (CH); 
114.64 (2 CH); 113.87 (C); 103.95 (C); 55.56 (CH3). GC/MS: 278 (M+H). Anal. Calcd for 
(C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 64.99; H, 3.97; N, 25.19. 
9.1.3.10. (E)-2-(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3-(4-bromophenyl)acrylonitrile (9c). 
Yield: 36%. M.p. = 169-170 °C. 1H-NMR (CDCl3): δ 9.56 (s,1H, CH-4); 8.74 (d, 1H, CH-6, J = 5.6 
Hz); 7.99 (s, 1H, CH); 7.88 (d, 1H, CH-7, J = 5.6 Hz); 7.80 (d, 2H, CH-3′,5′, J = 8.4 Hz); 7.70 (d, 
2H, CH-2′,6′, J = 8.4 Hz). 13C-NMR (CDCl3): δ 146.77 (CH); 145.34 (CH); 143.44 (C); 139.34 
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(CH); 135.16 (C); 132.85 (2xCH); 131 (2xCH); 128.97 (C); 127.14 (C); 114.17 (C); 106.36 (C); 
105.03 (CH). GC/MS: 326 (M+H). Anal. Calcd for (C14H8BrN5): C, 51.56; H, 2.47; Br, 24.50; N, 
21.47. Found: C, 51.60; H, 2.51; Br, 24.52; N, 21.43. 
9.1.3.11. (E)-2-(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3-(p-tolyl)acrylonitrile (9d). Yield: 51%. 
M.p. = 180-181 °C. 1H-NMR (DMSO-d6): δ 9.64 (s, 1H, CH-4); 8.74 (d, 1H, CH-6, J = 5.4 Hz), 
8.27 (s, 1H, CH); 8.1 (d, 1H, CH-7, J = 5.8 Hz); 7.92 (d, 2H, CH=, J = 7.8 Hz); 7.45 (d, 2H, CH=, J 
= 7.8 Hz); 2.42 (s, 3H, CH3). 13C-NMR (CDCl3): δ 146.86 (CH); 145.32 (CH); 143.52 (C); 143.36 
(C); 141.58 (CH); 135.19 (C); 130.23 (2 CH); 129.95 (2 CH); 127.33 (C); 114.08 (C); 105.05 (CH); 
104.63 (C); 21.80 (CH3). GC/MS: 262 (M+H). Anal. Calcd for (C15H11N5): C, 68.95; H, 4.24; N, 
26.80. Found: C, 69.98; H, 4.21; N, 26.76. 
9.1.3.12. (E)-2-(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3-(4-methoxyphenyl)acrylonitrile (9e). 
Yield: 94%. M.p.: 195-196.7°C. 1H-NMR (DMSO-d6): δ 9.63 (s, 1H, CH-4); 8.73 (d, 1H, CH-6, J = 
6.2 Hz), 8.22 (s, 1H, CH); 8.07 (d, 1H, CH-7, J = 6.2 Hz); 8.02 (d, 2H, CH=, J = 8.8 Hz); 7.21 (d, 
2H, CH=, J = 8.8 Hz); 3.88 (s, 3H, CH3). 13C-NMR (CDCl3): δ 163.07 (C); 146.39 (CH); 145.26 
(CH); 145.20 (CH); 144.01 (C); 141.62 (CH); 135.37 (C); 132.04 (2 CH); 122.61 (C); 114.99 (2 
CH); 113.89 (C); 105.01(CH); 102.81 (C); 55.29 (CH3). GC/MS: 278 (M+H). Anal. Calcd for 
(C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 64.99; H, 3.97; N, 25.21. 
9.1.3.13. (E)-2-(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3-(naphthalen-2-yl)acrylonitrile (9f). 
Yield: 43 %. M.p. = 188-189 °C. 1H-NMR (CDCl3): δ 9.57 (s, 1H, CH-4); 8.74 (d, 1H, CH-6, J = 
6.0 Hz); 8.33 (s, 1H, CH); 8.15 (s, 1H, CH); 8.10 (d, 1H, CH-7, J = 6.0 Hz); 8.01-7.57 (m, 6H, CH). 
13C- NMR (CDCl3): δ 146.62 (CH); 145.29 (CH); 143.42 (C); 141.22 (CH); 135.28 (C); 134.90 (C); 
132.96 (C); 132.21 (CH); 129.46 (CH); 128.07 (CH); 128.79 (CH); 127.96 (CH); 127.48 (CH); 
124.45 (CH); 114.14 (C); 113.49 (C); 105.81 (C); 105.13 (CH). GC/MS: 298 (M+H). Anal. Calcd 
for (C18H11N5): C, 72.72; H, 3.73; N, 23.56. Found: C, 72.68; H, 3.80; N, 23.54. 
9.1.3.14. (E)-2-(2H-[1,2,3]triazolo[4,5-c]pyridin-2-yl)-3-(p-tolyl)acrylonitrile (10d). Yield: 
46.9%. M.p. = 194-195°C. 1H-NMR (DMSO-d6): δ 9.65 (s, 1H, CH-4); 8.84 (s, 1H, CH,), 8.56 (d, 
1H, CH-6. J = 5.4 Hz); 8.03 (d, 1H, CH-7, J = 5.4 Hz); 8.00(d, 2H, CH-2′,6′, J = 8.8 Hz); 7.45 (d, 
2H, CH-3′,5′, J = 8.8 Hz); 2.42 (s, 3H, CH3). 13C-NMR (CDCl3): δ 146.74 (C); 145.57 (CH); 144.00 
(C); 143.84 (CH); 141.76 (C); 139.70 (CH); 130.46 (2 CH); 129.95 (2 CH); 127.02 (C); 112.81 (C); 
11.84 (CH); 110.94 (C); 21.84 (CH3). GC/MS: 262 (M+H). Anal. Calcd for (C15H11N5): C, 68.95; 
H, 4.24; N, 26.80. Found: C, 68.93; H, 4.27; N, 26.79. 
9.1.3.15. (E)-2-(2H-[1,2,3]triazolo[4,5-c]pyridin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (10e). 
Yield: 56%. M.p.: 171-172 °C. 1H-NMR (DMSO-d6): δ 9.65 (s, 1H, CH-4); 8.83 (s, 1H, CH,), 8.55 
(d, 1H, CH-6. J = 6 Hz); 8.12 (d, 2H, CH-2′,6′, J = 8.6 Hz); 8.04 (d, 1H, CH-7, J = 6.2 Hz); 7.22 (d, 
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2H, CH-3′,5′, J=8.6 Hz); 3.89 (s, 3H, CH3). 13C-NMR (DMSO-d6): δ 163.34 (C); 146.71 (C); 
145.42 (CH); 143.75 (CH); 141.73 (C); 139.32 (CH); 132.68 (2 CH); 122.34 (C); 115.05 (2 CH); 
113.21 (C); 111.47 (CH); 109.38 (C); 55.66 (CH3). GC-MS: 278 (M+H). Anal. Calcd for 
(C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 65.00; H, 4.02; N, 25.29. 
9.1.3.16. (E)-2-(3H-[1,2,3]triazolo[4,5-c]pyridin-3-yl)-3-(p-tolyl)acrylonitrile (11d). Yield: 16%. 
M.p. = 152–153 °C. 1H.NMR (CDCl3): δ 9.50 (s, 1H, CH-4); 8.68 (d, 1H, CH-6, J = 5.6 Hz); 8.06 
(d, 1H, CH-7, J = 5.6 Hz); 7.96 (s, 1H, CH); 7.86 (s, 2H, CH-2′,6′, J = 8 Hz); 7.37 (d, 2H, CH-3′,5′, 
J = 8 Hz); 2.47 (s, 3H, CH3). 13C-NMR (CDCl3): δ 149.98 (C); 143.87 (C); 142.73 (CH); 141.91 
(CH); 134.82 (CH); 130.2 (2 CH); 130.0 (2 CH); 129.15 (C); 128.80 (C); 114.51 (CH); 113.65 (C); 
104.79 (C); 21.82 (CH3). GC/MS: 262 (M+H). Anal. Calcd for (C15H11N5): C, 68.95; H, 4.24; N, 
26.80. Found: C, 69.00; H, 4.26; N, 26.78. 
9.1.3.17. (E)-2-(1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3-(4-methoxyphenyl)acrylonitrile (11e). 
Yield: 30%. M.p. = 161-162 °C. 1H-NMR (DMSO-d6): δ 9.56 (s, 1H, CH-4); 8.66 (d, 1H, CH-6, J = 
5.8 Hz), 8.33 (s, 1H, CH); 8.25 (d, 1H, CH-7, J = 5.8 Hz); 8.04 (d, 2H, CH-2′,6′, J = 9 Hz); 7.21 (d, 
2H, CH-3′,5′, J = 9 Hz); 3.88 (s, 3H, CH3). 13C-NMR (DMSO-d6): δ 162.42 (C); 148.66 (C); 143.06 
(CH); 141.74 (CH); 136.35 (CH); 135.43 (C); 132.41 (2 CH); 128.74 (C); 122.71 (C); 114.87 (2 
CH); 114.54 (C); 113.53 (CH); 105.98 (C); 55.62 (CH3). GC/MS = 278 (M+H). Anal. Calcd for 
(C15H11N5O): C, 64.97; H, 4.00; N, 25.26. Found: C, 65.01; H, 4.03; N, 25.30. 
 
9.2. Cytotoxicity assay  
All cancer cell lines were obtained from the German Collection of Microbiology and Cell Culture 
(DSMZ, Braunschweig, FRG). 
Human peripheral mononuclerar blood cells (P10588), human pulmonary fibroblasts (P10551), and 
human prostate epithelial cells (P10953) were purchased from Innoprot (Derio, Spain). 
Exponentially growing cells derived from human hematological tumors - CCRF-CEM (ACC-240, 
T-cell leukemia) and HL-60 (acute myeloid leukemia) - were seeded at an initial density of 1 x 105 
cells/mL in 96 well plates in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 
100 units/mL penicillin G and 100 g/mL streptomycin. Human cell lines derived from solid 
tumors - HeLa (ACC-57, cervix carcinoma), DU145 (ACC-261, prostate carcinoma), MCF-7 
(ACC-115, breast adenocarcinoma), A-427 (ACC-234, small cell lung carcinoma), LCLC 103H 
(ACC-384, large cell lung carcinoma), DAN-G (ACC-249, pancreas carcinoma), and 5637 (ACC-
35, urinary bladder carcinoma) - were also seeded at 1x105 cells/mL in 96 well plates in specific 
media supplemented with 10% FCS and antibiotics as above. Cell cultures were then incubated at 
37°C in a humidified, 5% CO2 atmosphere in the absence or presence of serial dilutions of test 
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compounds. Cell viability was determined after 96 h at 37°C by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide (MTT) method. 
Each test was prepared in triplicate, and the experiments were carried out three times. EC50 values 
were obtained by nonlinear regression (GraphPad Prism v. 6.0) and represent the concentration at 
which cell growth was inhibited by 50%.  
 
9.3. In vitro tubulin polymerization assay 
The purity of tubulin was estimated to be >97% using Coomassie Brilliant Blue stained SDS-
PAGE. Tubulin was re-suspended in a buffer containing 25 mM PIPES, 1 mM EGTA, and 3 mM 
MgCl2 with 1 M glutamate and was incubated without or with different concentrations of title 
compounds for 10 min on ice. After 10 min, 1 mM GTP was added to the reaction mixtures, and 
subsequently, the assembly kinetics of tubulin was monitored at 350 nm (37 °C) for 20 min using 
Spectramax M2e multi-mode microplate reader (Molecular Devices, CA, USA). Each test was run 
in triplicate. The steady-state tubulin assembly level in the absence of inhibitor was set to 100%. 
ITP IC50 values were obtained by sigmoidal fitting of steady state levels of tubulin assembly vs. 
drug concentration and represent the concentration for 50% inhibition of the maximum tubulin 
polymerization level. Three independent sets of experiments were performed. 
 
9.4. Cell cycle analysis 
To determine the effect of compounds 6c and 6d on the cell cycle, cells were seeded in 12-well 
plates at a density of 105 cells/mL and allowed to attach for 24 h. Cells were then incubated in the 
presence or absence (DMSO) of compounds 6c and 6d at a concentration of 2 M for 24 h. DMSO 
was used for control. Next, cells were collected, washed and fixed in 70% ethanol in PBS at -20 °C. 
After leaving overnight, the fixed cells were pelleted and stained with Propidium Iodide (25 
mg/ml)) in the presence of RNase A (40 mg/mL) containing 0.1% Triton X-100 for 30 min at 37 °C 
in dark. About 10,000 events were analyzed using a FACSCalibur flow cytometry system (BD 
BioSciences, San Jose, CA, USA). Distribution of cells in cell cycle was determined using the BD 
FACStation Software (v. 6.1). 
 
9.5. Preliminary determination of the dissociation constant of compounds 6c to tubulin in 
vitro by fluorescence spectroscopy 
Tubulin was incubated in the absence and presence of different concentrations of compound 6c for 
10 min at 37 °C. Tryptophan fluorescence of tubulin in the presence and absence of compound 6c 
was monitored using an excitation wavelength of 295 nm in a 0.3 cm path length cuvette (FP-6500 
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spectrofluorometer JASCO, Tokyo, Japan). The dissociation constant Kd for the binding interaction 
of 6c and tubulin was calculated by fitting the change in fluorescence data using GraphPad Prism 
software (v. 6.0). Three independent sets of experiments were performed. 
 
9.6. Determination of the dissociation constant and tubulin binding site of compounds (6-8) 
and (9-11) by Isothermal Titration Calorimetry (ITC). 
Isothermal titration calorimetry (ITC) experiments were performed with a MicroCal PEAQ-ITC 
calorimeter (Malvern, UK) at 37°C (cell volume = 280 µL). Thermodynamics of Tubulin/ligand 
complex formation was investigated in PEM buffered solutions with 0.1 mM GDP, as stabilizer 
agents. Specifically, a solution of tubulin (50µM, sample cell) was titrated with 19 step-by-step 
injections of 2µL volume of each compound (600 µM, syringe). Solutions and buffer were degassed 
for 30 min at room temperature under stirring at 750 rpm prior to each experiment. All experiments 
were run in triplicate. Data acquisition and analysis were performed using inbuilt Origin 7.0 to 
determine the binding stoichiometry (n) and thermodynamic parameters of the binding reaction. 
 
9.7. Molecular modeling 
All simulations were carried out using the Pmemd modules of Amber 16 [17], running on own 
CPU/GPU calculation cluster. Molecular graphics images were produced using the UCSF Chimera 
package (v.1.10) [18]. Chimera is developed by the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311). 
All other graphs were obtained using GraphPad Prism (v. 6.0). 
 
9.7.1 Docking procedure 
The optimized structures of title compounds were docked into the tubulin binding pockets using the 
optimized 3D structure of the tubulin taken from our previous work [8]. All docking experiments 
were performed with Autodock 4.2.6/Autodock Tools 1.4.6 [19] on a win64 platform. The resulting 
docked conformations were clustered and visualized; then, the structure of each resulting complex 
characterized by the lowest Autodock interaction energy in the prevailing cluster was selected for 
further modeling. 
 
9.7.2. Molecular dynamics simulations 
Each ligand/tubulin complexes obtained from the docking procedure was further refined in Amber 
16 using the quenched molecular dynamics (QMD) method as previously described [see, for 
example, 8, 20-22 and reference therein]. Next, the best energy configuration of each complex 
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resulting from QMD was subsequently solvated by a cubic box of TIP3P water molecules [23] 
extending at least 10 Å in each direction from the solute. The system was neutralized and the 
solution ionic strength was adjusted to the physiological value of 0.15M by adding the proper 
amounts of Na+ and Cl- ions. Each solvated system was relaxed (500 steps of steepest descent 
followed by 500 other conjugate-gradient minimization steps) and then gradually heated to the 
target temperature of 37°C in intervals of 50 ps of constant volume-constant temperature (NVT) 
molecular dynamics (MD) simulations (Verlet integration method, time step = 1.0 fs). The 
Langevin thermostat was used to control temperature. During this phase of MD, the protein was 
restrained with a force constant of 2.0 kcal/(mol Å), and all simulations were carried out with 
periodic boundary conditions. Subsequently, the density of the system was equilibrated via MD 
runs in the isothermal-isobaric (NPT) ensemble, with a time step of 1 fs. All restraints on the 
protein atoms were then removed, and each system was further equilibrated using NPT MD runs at 
37°C. Three equilibration steps were performed (4 ns each, time step = 2.0 fs). System stability was 
monitored by the fluctuations of the root-mean-square-deviation (rmsd) of the simulated position of 
the backbone atoms of tubulin with respect to those of the initial protein model. The equilibration 
phase was followed by a data production run consisting of 50 ns of MD simulations in the NVT 
ensemble. Data collection was performed on over the last 20 ns of each equilibrated MD trajectory 
were considered for statistical data collections. 1000 trajectory snapshots were analyzed for each 
compound/tubulin complex. 
 
9.7.3. Free energy of binding analysis 
The free energy of binding ∆Gb and its major components (∆Hb and T∆Sb) between the selected 
compounds and tubulin was estimated by resorting to the well-validated Molecular 
Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) approach [24] implemented in Amber 
16. The per residue binding free energy decomposition (interaction spectra) was carried out using 
the Molecular Mechanics/Generalized Boltzmann Surface Area (MM/GBSA) approach [25,26], and 
was based on the same snapshots used in the binding free energy calculation. 
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Highlights 
We present a series of E isomers of triazolo[4,5-b/c]pyridin-acrylonitrile derivatives 
All the derivates have been investigated for their antiproliferative activity 
Fluorescence-based assays prove that derivatives interfere with tubulin polymerization. 
Isothermal titration calorimetry provides full tubulin/compound binding thermodynamics. 
In silico modelling of interactions between tubulin and the title compounds is reported 
